Salehi Retina Institute Inc. | Huntington Beach, CA

Research site

(Unclaimed)

Location

7777 Edinger Avenue, Suite 234, Huntington Beach, California, United States of America

Site insights

Top conditions

Top treatments

UBX1325

KHK4951

Foselutoclax

Iptacopan

THR-687

KUS121

THR-149

ONL1204

Fenofibrate

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

6 of 14 total trials

A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular Degeneration

The purpose of this study is to assess the effect of Iptacopan to prevent conversion of early or intermediate age-related macular degeneration (AMD)...

Enrolling

Age-Related Macular Degeneration

Drug: Placebo

Drug: Iptacopan (LNP023)

A Study of the Efficacy and Safety of KUS121 in Participants With Acute Non-Arteritic Central Retinal Artery Occlusion (CRAO) (GION)

Central retinal artery occlusion (CRAO) is an ophthalmologic emergency which leads to severe and permanent vision loss. There is no evidence-based th...

Enrolling

Central Retinal Artery Occlusion

Drug: KUS121 high dose

Drug: Sham procedure

Assess the Efficacy and Safety of Repeat Intravitreal Injections of Foselutoclax (UBX1325) in Patients With DME (ASPIRE)

The goal of this clinical trial is to assess the efficacy and safety of multiple doses of foselutoclax (UBX1325) in patients with Diabetic Macular Ed...

Active, not recruiting

Edema

Diabetic Macular Edema

Drug: foselutoclax

Drug: Aflibercept

Fenofibrate for Prevention of DR Worsening (Protocol AF)

This randomized trial will evaluate the effect of fenofibrate compared with placebo for prevention of diabetic retinopathy (DR) worsening through 6 y...

Enrolling

Diabetic Retinopathy

Other: Placebo

Drug: Fenofibrate